RxDoctor Payments Data

Thomas Grischow

Optometrist · Warren, OHNPI 1932132818

Payments from drug & device makers

$4,565in general payments, 2019–2025

Across 199 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$593
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$410
  • Bausch & Lomb Americas Inc.$391
  • Oyster Point Pharma, Inc.$275
  • Johnson & Johnson Vision Care, Inc.$268
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,565 in reported general payments places this provider in the 90th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$118,039
Medicare patients
691
Services billed
1,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost91$60,935
RestasisCyclosporine30$38,641
CombiganBrimonidine Tartrate/Timolol51$23,078
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol111$21,522
VyzultaLatanoprostene Bunod24$10,622
Latanoprost716$8,919
Alphagan PBrimonidine Tartrate11$3,348
Brimonidine Tartrate79$3,160
Travoprost16$2,514
Timolol Maleate221$2,187
Prednisolone Acetate39$1,687
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha87$980
Dorzolamide Hcl36$735
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat46$506
ErythromycinErythromycin Base13$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$593$126,002183 claims
Bausch & Lomb Americas Inc.Vyzulta$391$10,62224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Warren

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →